Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
73 participants
OBSERVATIONAL
2017-01-03
2020-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Characteristics Of ALK-positive and ROS1-positive Adults Patients Non-Small Cell Lung Cancer (NSCLC) Treated With Crizotinib Within General Hospitals
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)
NCT02679170
A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer
NCT01500824
Crizotinib in ALK Rearranged Non-small-cell Lung Cancer
NCT04317651
ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants
NCT02737501
A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer
NCT03155009
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Locally advanced or metastatic NSCLC
* Patient ALK gene rearrangement or ROS1 gene rearrangement
* Patient having initiated in the previous 3 months or patient initiating crizotinib treatment regardless of the line of treatment
* Patient followed up by a physician in a hospital pulmonary medicine department
* Subject of reproductive age, using an effective method of contraception
* Patient informed verbally and in writing on the study and having consented to his/her personal data being collected within the scope of the study.
* Patient included within the scope of an interventional therapeutic trial
* Patient not presenting with ALK gene rearrangement or ROS1 gene rearrangement
* Patient not available for follow-up throughout the duration of the study
* Patient deemed to be incapable of responding to the study questions for linguistic, cognitive or organisational reasons.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
French College of General Hospital Pneumologists (CPHG)
OTHER
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Intercommunal du Pays d'Aix-Pertuis,Service de Pneumologie
Aix-en-Provence, , France
Clinique de l Europe
Amiens, , France
Hopital Robert Ballanger, Service de Pneumologie
Aulnay-sous-Bois, , France
Centre Hospitalier d Avignon
Avignon, , France
Centre Hospitalier de Beauvais
Beauvais, , France
Centre Hospitalier General Beziers, Service De Pneumologie
Béziers, , France
Centre Hospitalier de Cannes
Cannes, , France
Centre Hospitalier Chalon sur Saone William Morey
Chalon-sur-Saône, , France
Centre Hospitalier Metropole de Savoie-Site de Chambery
Chambéry, , France
Hopitaux Civils de Colmar - Hopital Louis Pasteur
Colmar, , France
Centre Hospitalier ALPES LEMAN
Contamine-sur-Arve, , France
Centre Hospitalier Intercommunal Frejus
Fréjus, , France
Centre Hospitalier Départemental Les Oudairies
La Roche-sur-Yon, , France
CHD Vendee
La Roche-sur-Yon, , France
Le Mans Hospital Center
Le Mans, , France
Centre Hospitalier des Deux Vallees - Longjumeau BP 125
Longjumeau, , France
Hopital Europeen - Service de Pneumologie
Marseille, , France
Centre Hospitalier de Macon
Mâcon, , France
GHR Mulhouse Sud Alsace
Mulhouse, , France
Centre Hospitalier de l'Agglomeration de Nevers
Nevers, , France
Centre Hospitalier Regional d Orleans
Orléans, , France
Centre Hospitalier Annecy Genevois
Pringy, , France
Groupe Hospitalier Sud Reunion
Saint Pierre La Réunion, , France
Hopitaux du Leman
Thonon-les-Bains, , France
Centre Hospitalier de Troyes, Service de Pneumologie - Oncologie Thoracique
Troyes, , France
Centre Hospitalier de Villefranche sur Saone - BP80436
Villefranche-sur-Saône, , France
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALK-2016-CPHG
Identifier Type: OTHER
Identifier Source: secondary_id
A8081060
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.